Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

@article{Carella2007DurableRI,
  title={Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission},
  author={Angelo Michele Carella and Enrica Lerma},
  journal={Annals of Hematology},
  year={2007},
  volume={86},
  pages={749-752}
}
In the present report, we address the question if the reduction of standard dosage of imatinib mesylate (IM) in imatinib-intolerant chronic myeloid leukemia (CML) patients with undetectable residual disease may impair their outcome. Four patients are described. The median follow up from the beginning of IM therapy was 35 months (33–59). The median duration of real-time quantitative polymerase chain reaction (RQ-PCR) negativity on IM 200 mg daily was 17months (4–37). We hypothesize that in IM… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
4 Extracted Citations
10 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 10 references

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual Ann Hematol

  • M Bocchia, S Gentili, E Abruzzese
  • 2005
1 Excerpt

— a Europe Against Cancer Program

  • F Michor, TP Hughes, Y Iwasa

Similar Papers

Loading similar papers…